Retatrutide Cost: No Price Yet, and My Estimate Is $450 to $650 a Month
I paid Lilly’s self-pay price for Zepbound for months, and retatrutide has no announced price yet, so here is what Lilly’s own price ladders imply.
GLP-1, Preventive Health
GLP-1
GLP-1, Preventive Health
Does CagriSema Have a Brand Name Yet?
CagriSema has no announced brand name as of September 4, 2026. Novo Nordisk owns eleven invented names it could use, and it bought the matching web address for only six of them.
GLP-1, Healthcare
Is CagriSema Covered by Medicare? Not Yet, and Here Is What Would Change That
CagriSema is not approved, so Medicare does not cover it. Here are the three routes after the FDA decides: the $50 Medicare GLP-1 Bridge, regular Part D, or the CagriSema cost without insurance.
GLP-1, Healthcare
CagriSema vs Zepbound: The New Combo Couldn’t Prove It Matches the Drug I’m On
Novo’s own head-to-head could not show CagriSema was as good as tirzepatide. I take Zepbound myself, and I go through both sets of numbers, plus the three brand names Novo has registered, including Wegovamy.
GLP-1, Preventive Health
Does Retatrutide Have a Brand Name Yet?
Retatrutide still has no brand name. But Lilly filed 20 new trademarks in a month and 19 are built on reta, from VYNRETA to YEZRETA. Here is the whole list, which domains Lilly quietly bought first, and what happened the last time it did this.
GLP-1, Preventive Health
Retatrutide vs Zepbound: Is Lilly’s Next Weight-Loss Shot Worth Waiting For?
Retatrutide beat Zepbound’s numbers in its own trials, and it did not need its top dose to do it. I take Zepbound, I lost about 170 pounds on it, and I am staying put.
GLP-1, Heart & Bloodwork
Mounjaro Just Got a Heart Indication. The Trial Behind It Didn’t Beat the Older Drug.
The FDA approved Mounjaro today to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who are at high risk for those events. That is a real expansion, and for a lot of people it is genuinely good news. It is also going to be reported badly by
GLP-1
Sam Sulek’s NewBioRx Sells “Research Only” Retatrutide. A NewBioRx-Branded Site Showed You How to Inject It, Until This Weekend.
Sam Sulek’s peptide company sold retatrutide in a pre-filled pen “for research use only,” while a site under the same NewBioRx branding walked you through putting it in your body. On Sunday afternoon the pen vanished from the store and the instructions site went dark. The vials are still for sale.
GLP-1
There’s No Legal Retatrutide to Buy. Lilly Just Sued Six Sellers of It.
Eli Lilly just sued six sellers of retatrutide. The catch is that the drug isn’t approved anywhere, so there is no legitimate version to buy. Whatever these sites are shipping came from outside the drug supply.
GLP-1
Insurance Won’t Cover Your GLP-1? The Drug Price Is Mostly Set. Shop the Prescribing Service: $108 to $1,678 a Year.
When insurance says no, the drug costs what LillyDirect and NovoCare charge, just about wherever you buy it. The prescribing service is the part you can shop, and it runs from about $100 to nearly $1,700 a year.